


# Prolonged *in vivo* expression and anti-tumor response of DNA-based anti-HER2 antibodies

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1:** (A) Plasma anti-trastuzumab antibodies, measured with a drug-sensitive ELISA, in BALB/c mice that received either one or two i.v. injections of 0.2 mg/kg trastuzumab protein. (B) Plasma trastuzumab concentrations of the ‘single pTras’ and ‘double pTras’ groups. The latter received an additional intramuscular (i.m.) pCAG-tras dose two weeks after the first dose. (C) pCAG-tras therapeutic experiment in athymic nude mice: individual tumor volumes of the different treatment groups. Abbreviations; i.v.: intravenous.